Earnings Analyzer
Stock earnings page

VIRTUS INVESTMENT PARTNERS INC (VRTS)

Track the next or latest earnings date for VIRTUS INVESTMENT PARTNERS INC, review consensus estimates, and see cached AI analysis for recent quarterly results.

Recent earnings news

Virtus Investment Partners (VRTS) Could Be 35% Undervalued On Fresh Mutual Fund Attention - Simply Wall St News
simplywall.st · 2 days ago

Why recent mutual fund attention matters for Virtus Investment Partners stock Recent coverage highlighting three Virtus mutual funds for long term investors, citing performance, rankings, and relatively low expenses, has put fresh attention on Virtus Investment Partners (VRTS) and what that ...

Does Analyst Praise for Virtus (VRTS) Funds Reveal a Durable Multi‑Boutique Advantage or Just Timing? - Simply Wall St News
simplywall.st · 3 days ago

In recent analyst coverage, several Virtus Investment Partners mutual funds, Silvant Focused Growth (PGWAX), Newfleet Multi-Sector S/T Bd (PSTCX), and Ceredex Mid-Cap Value Equity (SAMVX), were highlighted for solid multi-year performance records and below-category-average expense ratios, drawing ..…

Dividend Growth Stock List: 8 Names Yielding Up To 8.3%
www.forbes.com · 2 days ago

So what does it mean when earnings come in at more than double the forecast? It means these companies have plenty of room—and reason—to hand more of that cash back to us.

Why Vertiv (VRT) Stock Is Up Today
finance.yahoo.com · 12 hours ago

Shares of data center products and services company Vertiv (NYSE:VRT) jumped 5.6% in the afternoon session after the company announced the opening of a new manufacturing facility in Johor, Malaysia, to meet surging demand for its AI and high-density computing infrastructure.

Viatris (VTRS): Most Undervalued NASDAQ Stocks to Buy Right Now
finance.yahoo.com · 2 days ago

Viatris Inc. (NASDAQ:VTRS) is one of the 10 Most Undervalued NASDAQ Stocks to Buy Right Now. On June 29, Viatris announced positive top-line results from a Phase 3 clinical trial of VR-205 (targeted-release budesonide) in Japanese adults with primary immunoglobulin A nephropathy (IgAN).

Upcoming earnings date

Jul 31, 2026

Time not specified

Fiscal quarter: 2026-06-30

EPS estimate: $6.03

Revenue estimate: N/A

Market cap: N/A

Analysis snapshot

No cached AI earnings analysis is available for this stock yet. Check back after the company reports or open the app to generate a fresh analysis.

Recent earnings history

Browse the calendar week
Date Quarter Report window EPS est. Revenue est.
Jul 31, 2026 2026-06-30 Time not specified $6.03 N/A
Feb 06, 2026 2025-12-31 Time not specified $6.41 N/A